Pulse8 Announces New Chief Medical Officer

Christopher L. Vojta, M.D., M.B.A., M.S.C.E. to Support Risk Adjustment Activities and Oversight of Clinical Outcomes

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dr. Christopher Vojta

Customers can rely on the fact that Pulse8 has the best identification, stratification and sequencing software in the industry.

Annapolis, MD (PRWEB) March 13, 2014

Pulse8 Inc., a cutting-edge big data healthcare analytics and technology company focused on risk adjustment solutions for the Commercial Health Exchanges (HIX) and Medicare Advantage markets announced today that it appointed Dr. Christopher Vojta as its Chief Medical Officer.

Dr. Vojta will provide strategic direction and support of the design, implementation, and adoption of cutting-edge healthcare technology and analytics products serving the Commercial Health Exchange and Medicare Advantage markets. He will also represent Pulse8’s mission and values in the oversight of risk adjustment, medical management, case and disease management, utilization review, and all decisions with clinical impact.

Dr. Vojta has 15 years of experience in various senior positions in health care including UnitedHealth Group, Deloitte Consulting and Wyeth Pharmaceuticals. In his leadership roles, he successfully launched major product innovations including Medicare Advantage Chronic Illness Special Needs Plans, ran the Medical Management Practice of Deloitte Consulting, and launched a Medical Management IT Consulting Practice. In addition, he was head of U.S. Medical Affairs for Wyeth, which included all of Global Health Outcomes Research, Opinion Leaders, U.S. Medical Science Liaison Group and U.S. Call Center.

“The appointment of Chris Vojta as Chief Medical Officer reflects Pulse8’s leadership position as health plans across the country rely on our products and expertise to ensure precision in their big data, analytics, and risk adjustment initiatives”, commented John Criswell, Founder and CEO. “As the big data and analytics leader, our integrated approach and clinical value for our customers will be strengthened by Dr. Vojta’s experience.”

In accepting this position, Dr. Vojta commented: “Customers can rely on the fact that Pulse8 has the best identification, stratification and sequencing software in the industry. In this new era of health care, plans have no choice but to be very selective in deciding which interventions to deploy. Pulse8 software offers unique analytics and visualization to detect and drive the least costly intervention achieving the highest financial performance.”

Dr. Vojta is a graduate of Yale University and holds MD, MBA and MS in Clinical Epidemiology from the University of Pennsylvania’s Wharton School and Medical School. In addition, he serves on several boards.

About Pulse8 Inc.
Pulse8 is a cutting-edge healthcare technology and analytics provider that delivers an unprecedented view into risk adjustment so health plans can achieve the highest financial impact in the Commercial Health Exchanges (HIX) and Medicare Advantage markets. Its proprietary algorithms move beyond traditional methods and data sources to make predictions about what individual members require next, ultimately closing gaps in care and increasing precision with risk adjustment initiatives. Pulse8 offers innovative and unique methodologies in its Risk Adjustment Analytics Suite to ensure its clients outperform the marketplace. Its transparent and flexible business intelligence tools ‎give real-time visibility into member and provider behaviors allowing clients to apply the most cost-effective and appropriate interventions. For more company information, please contact Pulse8 at (410) 928.4218 or visit http://www.Pulse8.com and follow Pulse8 on Twitter @Pulse8News


Contact

Attachments